HCM
KERX

Harvey Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Harvey Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-35,100
Closed -$163K – 89
2017
Q4 		$163K Buy
+35,100
New +$193K 0.06% 81
2014
Q3 		– Sell
-932,400
Closed -$14.3M – 76
2014
Q2 		$14.3M Buy
932,400
+16,600
+2% +$235K 5.13% 2
2014
Q1 		$15.6M Buy
915,800
+25,300
+3% +$382K 6.22% 1
2013
Q4 		$11.5M Buy
890,500
+70,500
+9% +$842K 4.76% 6
2013
Q3 		$8.27M Buy
+820,000
New +$7.3M 4.2% 8

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Harvey Capital Management's KERX Position: Q1 2018 in Review

Harvey Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 35,100 shares — an estimated $163K sold.

Harvey Capital Management first reported a position in KERX in Q3 2013 and held it in 5 quarters. The position peaked at $15.6M in Q1 2014. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Harvey Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Harvey Capital Management sold 35,100 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $163K.
  • Harvey Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 5 quarters.
  • Harvey Capital Management's Keryx Biopharmaceuticals Inc position peaked at $15.6M in Q1 2014.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Harvey Capital Management's 13F filing for Q1 2018, filed 27 Apr 2018.